ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $95.00 at Credit Suisse Group

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its target price increased by Credit Suisse Group from $93.00 to $95.00 in a report published on Friday morning, The Fly reports. Several other equities analysts have also recently issued reports on the company. Mizuho reaffirmed a neutral rating and set a $20.00 price objective on shares of […]

Related Keywords

China ,Canada ,Markc Schneyer ,Stephen Davis ,Wipfli Financial Advisors ,China Universal Asset Management Co ,Advisors Inc ,Credit Suisse Group ,Acadia Pharmaceuticals ,Cantor Fitzgerald ,Pharmaceuticals Daily ,Securities Exchange Commission ,Royal Bank ,Pharmaceuticals Company Profile ,Pharmaceuticals Trading ,Lazard Asset Management ,Pharmaceuticals Inc ,Get Rating ,Suisse Group ,Exchange Commission ,Financial Advisors ,Universal Asset Management ,Nasdaq Acad ,Facad ,Medical ,Boost Price Target ,Credit Suisse Group Ag ,